CODEXIS INC (CDXS) Stock Price & Overview
NASDAQ:CDXS • US1920051067
Current stock price
The current stock price of CDXS is 1.6 USD. Today CDXS is down by -4.19%. In the past month the price increased by 36.75%. In the past year, price decreased by -37.25%.
CDXS Key Statistics
- Market Cap
- 145.392M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.52
- Dividend Yield
- N/A
CDXS Stock Performance
CDXS Stock Chart
CDXS Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to CDXS. When comparing the yearly performance of all stocks, CDXS is a bad performer in the overall market: 82.98% of all stocks are doing better.
CDXS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CDXS. CDXS may be in some trouble as it scores bad on both profitability and health.
CDXS Earnings
On March 11, 2026 CDXS reported an EPS of 0.11 and a revenue of 38.91M. The company beat EPS expectations (356.77% surprise) and beat revenue expectations (6.47% surprise).
CDXS Forecast & Estimates
13 analysts have analysed CDXS and the average price target is 6.71 USD. This implies a price increase of 319.69% is expected in the next year compared to the current price of 1.6.
For the next year, analysts expect an EPS growth of 21.54% and a revenue growth 9.08% for CDXS
CDXS Groups
Sector & Classification
CDXS Financial Highlights
Over the last trailing twelve months CDXS reported a non-GAAP Earnings per Share(EPS) of -0.52. The EPS increased by 42.22% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -29.75% | ||
| ROE | -87.03% | ||
| Debt/Equity | 0.79 |
CDXS Ownership
CDXS Latest News, Press Relases and Analysis
CDXS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 19.13 | 174.674B | ||
| DHR | DANAHER CORP | 22.3 | 134.434B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 124.29 | 41.625B | ||
| A | AGILENT TECHNOLOGIES INC | 16.63 | 31.592B | ||
| WAT | WATERS CORP | 20.58 | 29.388B | ||
| IQV | IQVIA HOLDINGS INC | 12.96 | 27.945B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 25.68 | 24.203B | ||
| ILMN | ILLUMINA INC | 23.76 | 19.356B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 29.26 | 17.309B | ||
| MEDP | MEDPACE HOLDINGS INC | 25.96 | 13.081B | ||
| RVTY | REVVITY INC | 15.59 | 9.588B | ||
| TEM | TEMPUS AI INC-CL A | N/A | 8.713B | ||
| TECH | BIO-TECHNE CORP | 23.14 | 8.071B |
Related stock screener links
View all stocks in the Life Sciences Tools & Services Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CDXS
Company Profile
Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. The company is headquartered in Redwood City, California and currently employs 146 full-time employees. The company went IPO on 2010-04-22. The company is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. The firm utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. The company is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) and other RNA-based therapeutics through an enzymatic route. The firm also uses the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics through its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
Company Info
IPO: 2010-04-22
CODEXIS INC
200 Penobscot Dr
Redwood City CALIFORNIA 94063 US
CEO: John J. Nicols
Employees: 146
Phone: 16504218100
CODEXIS INC / CDXS FAQ
Can you describe the business of CODEXIS INC?
Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. The company is headquartered in Redwood City, California and currently employs 146 full-time employees. The company went IPO on 2010-04-22. The company is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. The firm utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. The company is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) and other RNA-based therapeutics through an enzymatic route. The firm also uses the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics through its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
What is the current price of CDXS stock?
The current stock price of CDXS is 1.6 USD. The price decreased by -4.19% in the last trading session.
What is the dividend status of CODEXIS INC?
CDXS does not pay a dividend.
What is the ChartMill technical and fundamental rating of CDXS stock?
CDXS has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Should I buy CDXS stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CDXS.
What is the expected growth for CDXS stock?
The Revenue of CODEXIS INC (CDXS) is expected to grow by 9.08% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.